MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults
Allergan, and MAP Pharmaceuticals, today announced a collaboration within the United States for LEVADEX, a self-administered, orally inhaled therapy that has completed Phase III clinical development for the treatment of acute migraine in adults.